Isomorphic Labs, the AI drug-discovery company spun out of Google DeepMind in 2021, has closed a $5 billion Series C co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining and all existing backers participating. Building on AlphaFold, its simulation-model engine has produced positive preclinical results in oncology and immunology and underpins deals with Eli Lilly, Novartis and Johnson & Johnson; the new capital is aimed at moving candidates into clinical trials.
Companiesslug: greenoaks
Greenoaks
US growth-stage investment firm known for concentrated bets on high-conviction technology companies.
Curated Intelligence
TechCrunch AIT2·Industry
78 pts
IT之家 · IT业界T2·Industry
78 pts
Isomorphic Labs, Alphabet's AI-driven drug discovery unit led by Nobel laureate Demis Hassabis, has closed a $5 billion Series C round co-led by Greenoaks and Sequoia Capital, with a16z joining as a new investor and Alphabet continuing to commit heavily. The proceeds will fund foundational simulation models, expand internal and partnered drug candidate programs, and build global AI-driven bioengineering infrastructure.